Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Skye Bioscience, Inc. (NMUS)
|
Add to portfolio |
|
|
|
| Price: |
$0.05
| | Metrics |
| OS: |
971.5
|
M
| |
|
|
| Market cap: |
$50.5
|
M
| |
|
|
|
Net cash:
|
$462.8
|
k
| |
$0.00
|
per share
|
|
EV:
|
$50.1
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($12.0)
|
M
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross margin | | | | | | | | |
| Research and development | 6.0 | 2.9 | 1.9 | 2.2 | 0.3 | 0.3 | 0.9 | 0.6 |
| General and administrative | 6.1 | 4.9 | 4.3 | 4.4 | 4.4 | 3.5 | 3.5 | 3.7 |
| EBIT | -12.1 | -7.8 | -6.3 | -6.6 | -4.7 | -3.9 | -4.5 | -4.3 |
| EBIT margin | | | | | | | | |
| Pre-tax income | -19.5 | -8.5 | -6.6 | 1.1 | -19.2 | -3.1 | -3.2 | -4.8 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | | | | 0.2% | | | | |
| Net income | -19.5 | -8.5 | -6.6 | 1.1 | -19.2 | -4.1 | -3.5 | -4.8 |
| Net margin | | | | | | | | |
| |
| Diluted EPS | ($0.04) | ($0.02) | ($0.03) | $0.01 | ($0.16) | ($0.15) | ($0.18) | ($0.29) |
| Shares outstanding (diluted) | 555.3 | 406.6 | 231.4 | 169.6 | 121.2 | 27.9 | 18.9 | 16.9 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|